Over the years, several cancer-related biomarkers have been identified, which can be used to predict response to certain types of immunotherapy drugs. However, due to the inherent complexity of the immune microenvironment and differences in the genomic makeup of individual patients, most of these biomarkers have been proven to be insufficient in predicting how a